HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

This story was originally published by Healthbeat. Sign up for their public health newsletters at healthbeat.org/newsletters.

In this month’s issue, the Sexpert advises readers on how to navigate discussions of PrEP and sexual health while in the ...

USAID offers (or offered) training on preventing mass atrocities, recognizing that infringement on religious freedom is a key ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

The Supreme Court is slated to hear arguments from a group of conservatives who think that the Affordable Care Act is violating their religious rights — by offering coverage for an ...

Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the bioscience giant for allegedly using joint research to develop an ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

Truvada for PrEP, the name-brand version of the pill form of HIV prevention medication, was approved by the Food and Drug Administration in July 2012 for sexually active adults after having been ...

Positive expectations for biotech AI success should be tempered. AI optimizes existing knowledge but doesn't expedite drug approval or reduce costs compared to traditional methods. Be wary that ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware ...